Unit-dose repackaging
This article was originally published in The Tan Sheet
Executive Summary
FDA's six-month expiration date limitation for repackaged unit-dose drugs places registered and inspected repackaging firms "at a disadvantage" compared to drugstores, hospitals and nursing home facilities that repackage unit-dose drugs using a one-year expiration date pursuant to USP standards, Palm Harbor, Fla.-based Peiser & Associates says in recent citizen petition. Filed on behalf of several repackaging firms, petition asserts "hospitals and clinics who utilize outside packaging services prefer to receive at least a one-year expiration date" and urges FDA to enforce USP standards. Agency compliance policy guide states enforcement action will not be initiated solely on the basis of a repackaging firm's failure to have stability studies supporting expiration dates as long as dates do not exceed six months...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.